The EDIL3 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the EDIL3 gene in the MES-OV human ovarian cancer cell line. This heterogeneous loss-of-function model provides a robust system for studying EDIL3-dependent processes without the need for single-cell cloning, making it suitable for scalable functional assays in a mesenchymal cancer background.
MES-OV cells were originally derived from ascitic fluid of a patient with ovarian cancer and exhibit a stable mesenchymal-like phenotype with features of epithelial-mesenchymal transition (EMT). They serve as a well-established model for ovarian cancer metastasis and chemoresistance, displaying high invasiveness and altered matrix interactions, which are clinically relevant for investigating the roles of secreted factors like EDIL3 in tumor progression.
EDIL3 is a secreted extracellular matrix protein that functions as a ligand for integrin receptors ??v??3 and ??v??5. Binding of EDIL3 to these integrins activates focal adhesion kinase (FAK), which subsequently stimulates Src, PI3K/Akt, and ERK1/2 signaling cascades. These pathways regulate cell adhesion, migration, and angiogenesis. EDIL3 expression is upregulated by HIF-1?? under hypoxic conditions and by TGF-?? during EMT, linking tumor microenvironmental cues to enhanced metastatic potential. Disruption of EDIL3 therefore abolishes key integrin-mediated signals.
In the MES-OV context, EDIL3 knockout directly interrogates the contribution of integrin ligand signaling to ovarian cancer aggressiveness. Loss of EDIL3 impairs ??v??3/??v??5-mediated FAK and Akt activation, leading to reduced cell migration and invasion. This model enables dissection of EDIL3-specific effects, exploration of compensatory mechanisms, and assessment of therapeutic vulnerabilities in FAK- and Src-dependent pathways.
This polyclonal knockout cell population supports a range of functional assays, including cell migration (Boyden chamber), adhesion, and angiogenic tube formation assays. It is compatible with Western blotting for phospho-FAK and phospho-Akt, immunofluorescence for integrin clustering, and RNA-seq transcriptional profiling. In vivo, these cells can be used in xenograft tumor models to evaluate metastatic growth. For further information, please contact Ascent Research.
